Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionNissay Asset Management Corp /japan/ /adv
Latest Disclosed Ownership36,898 shares
Latest Disclosed Value $ 12,208,441
Nissay Asset Management Corp /japan/ /adv reports 3.03% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Nissay Asset Management Corp /japan/ /adv filed a 13F-HR form disclosing ownership of 36,898 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $10,541,759 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 35,813 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 3.03% during the quarter. The current value of the position is $9,611,929 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 36,898 1,085 3.03 12,208 -14.28 0.0647
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,813 19,238 116.07 14,241 88.42 0.0741
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,575 287 1.76 7,558 42.31 0.0417
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,288 74 0.46 5,311 21.31 0.0311
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,214 267 1.67 4,378 15.39 0.0285
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,947 324 2.07 3,795 -11.69 0.0231
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,623 -478 -2.97 4,297 9.82 0.0272
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,101 524 3.36 3,913 68.11 0.0259
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,577 319 2.09 2,328 -20.31 0.0161
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,258 485 3.28 2,921 11.62 0.0235
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,773 537 3.77 2,616 -3.22 0.0232
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,236 -280 -1.93 2,704 -7.02 0.0233
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,516 -194 -1.32 2,908 -16.82 0.0260
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,710 -48 -0.33 3,496 18.31 0.0334
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,758 556 3.91 2,954 42.64 0.0310
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,202 179 1.28 2,071 -9.56 0.0206
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,023 386 2.83 2,290 -0.99 0.0199
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,637 371 2.80 2,313 -7.66 0.0177
2021-11-10 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,266 1,913 16.85 2,505 30.13 0.0212
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,353 270 2.44 1,925 23.00 0.0169
2021-05-11 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,083 -289 -2.54 1,565 5.89 0.0154
2021-02-08 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,372 -168 -1.46 1,478 -12.02 0.0222
2020-10-20 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,540 474 4.28 1,680 2.50 0.0284
2020-07-27 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,066 1,455 15.14 1,639 56.69 0.0318
2020-05-05 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,611 400 4.34 1,046 -1.41 0.0266
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,211 -82 -0.88 1,061 42.03 0.0236
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,293 1,498 19.22 747 31.98 0.0185
2019-08-07 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,795 233 3.08 566 -19.94 0.0143
2019-05-03 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,562 394 5.50 707 35.18 0.0187
2019-02-06 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,168 507 7.61 523 -10.29 0.0159
2018-10-30 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,661 259 4.05 583 -7.61 0.0157
2018-08-08 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,402 -5,075 -44.22 631 -53.84 0.0185
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,477 160 1.41 1,367 -4.87 0.0427
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,317 11,317 1,437 0.0438
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.